ArticleJournal of advanced research2022
The applications of deep learning algorithms on in silico druggable proteins identification.
Article in Journal of advanced research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Artificial intelligence-driven precision treatment of reproductive medicine-related diseases: the optimal protocol choice for IVF-ET.Journal of advanced research · 2026Article
- Computational pathology-based artificial intelligence platform for the identification of common oral potentially malignant disorders.BMC oral health · 2026Article
- AI-Driven Drug Discovery: Focus on Targets for Solid Tumors.Pharmaceutics · 2026Review
- Article
- Protein Representation in Metric Spaces for Protein Druggability Prediction: A Case Study on Aspirin.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Multimodal deep learning for allergenic proteins prediction.BMC biology · 2025Article
- DrugTar improves druggability prediction by integrating large language models and gene ontologies.Bioinformatics (Oxford, England) · 2025Article
- Joint fusion of sequences and structures of drugs and targets for identifying targets based on intra and inter cross-attention mechanisms.BMC biology · 2025Article
- PLM-ATG: Identification of Autophagy Proteins by Integrating Protein Language Model Embeddings with PSSM-Based Features.Molecules (Basel, Switzerland) · 2025Article
- Applications of Artificial Intelligence in Drug Repurposing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Development and validation of a deep reinforcement learning algorithm for auto-delineation of organs at risk in cervical cancer radiotherapy.Scientific reports · 2025Article
- Article
- Repurposing FDA-Approved Drugs Against Potential Drug Targets Involved in Brain Inflammation Contributing to Alzheimer's Disease.Targets (Basel) · 2024Article
- Prediction of leukemia peptides using convolutional neural network and protein compositions.BMC cancer · 2024Article
- Comprehensive Research on Druggable Proteins: From PSSM to Pre-Trained Language Models.International journal of molecular sciences · 2024Article
- DPI_CDF: druggable protein identifier using cascade deep forest.BMC bioinformatics · 2024Article
- In silico protein function prediction: the rise of machine learning-based approaches.Medical review (2021) · 2023Review
- Article
- Targeting Protein-Protein Interfaces with Peptides: The Contribution of Chemical Combinatorial Peptide Library Approaches.International journal of molecular sciences · 2023Review
- QuoteTarget: A sequence-based transformer protein language model to identify potentially druggable protein targets.Protein science : a publication of the Protein Society · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe top priority in drug development is to identify novel and effective drug targets. In vitro assays are frequently used for this purpose; however, traditional experimental approaches are insufficient for large-scale exploration of novel drug targets, as they are expensive, time-consuming and laborious. Therefore, computational methods have emerged in recent decades as an alternative to aid experimental drug discovery studies by developing sophisticated predictive models to estimate unknown drugs/compounds and their targets. The recent success of deep learning (DL) techniques in machine learning and artificial intelligence has further attracted a great deal of attention in the biomedicine field, including computational drug discovery.
objectivesThis study focuses on the practical applications of deep learning algorithms for predicting druggable proteins and proposes a powerful predictor for fast and accurate identification of potential drug targets.
methodsUsing a gold-standard dataset, we explored several typical protein features and different deep learning algorithms and evaluated their performance in a comprehensive way. We provide an overview of the entire experimental process, including protein features and descriptors, neural network architectures, libraries and toolkits for deep learning modelling, performance evaluation metrics, model interpretation and visualization.
resultsExperimental results show that the hybrid model (architecture: CNN-RNN (BiLSTM) + DNN; feature: dictionary encoding + DC_TC_CTD) performed better than the other models on the benchmark dataset. This hybrid model was able to achieve 90.0% accuracy and 0.800 MCC on the test dataset and 84.8% and 0.703 on a nonredundant independent test dataset, which is comparable to those of existing methods.
conclusionWe developed the first deep learning-based classifier for fast and accurate identification of potential druggable proteins. We hope that this study will be helpful for future researchers who would like to use deep learning techniques to develop relevant predictive models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.